Diamond Hill Capital Management Inc. Has $42.93 Million Holdings in Illumina, Inc. $ILMN

Diamond Hill Capital Management Inc. reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,331 shares of the life sciences company’s stock after selling 15,626 shares during the quarter. Diamond Hill Capital Management Inc.’s holdings in Illumina were worth $42,933,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Elyxium Wealth LLC acquired a new position in shares of Illumina in the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new position in shares of Illumina in the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC boosted its holdings in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Royal Bank Of Canada assumed coverage on shares of Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Guggenheim upped their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group reduced their price objective on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Finally, Piper Sandler reduced their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $137.75.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares in the company, valued at approximately $508,696,976.32. The trade was a 2.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 330,160 shares of company stock valued at $48,028,308 in the last quarter. Corporate insiders own 2.90% of the company’s stock.

Illumina Stock Up 2.1%

NASDAQ:ILMN opened at $144.83 on Friday. The stock’s fifty day moving average price is $129.99 and its two-hundred day moving average price is $130.81. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The company has a market cap of $21.91 billion, a price-to-earnings ratio of 26.33, a P/E/G ratio of 2.35 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.